Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of fingolimod and its structural analog in preparation of cerebral hemorrhage treatment medicines

A technology with similar structure and fingolimod hydrochloride, applied in the field of fingolimod and its structural analogs, can solve problems such as no cerebral hemorrhage, and achieve the effects of expanding clinical indications, highlighting promotion prospects, and achieving remarkable curative effects

Inactive Publication Date: 2014-11-26
施福东 +10
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] In the prior art, fingolimod is only used to treat multiple sclerosis, and there is no application of this drug in the treatment of cerebral hemorrhage

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of fingolimod and its structural analog in preparation of cerebral hemorrhage treatment medicines
  • Application of fingolimod and its structural analog in preparation of cerebral hemorrhage treatment medicines
  • Application of fingolimod and its structural analog in preparation of cerebral hemorrhage treatment medicines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] 1. Preparation of drugs

[0025] Take 50g of fingolimod and 2450g of starch, mix 950g of starch with water to make a thin slurry, then gradually add the remaining starch and all of fingolimod to the slurry under stirring, stir all the ingredients evenly, make granules, and then Sieve, dry, and pack into capsules.

[0026] 2. Selection of experimental objects

[0027] Between March 2013 and December 2013, 11 patients with spontaneous subtentorial parenchymal hemorrhage with onset time less than 72 hours, hematoma volume between 5ml and 30ml, Glasgow coma index not less than 6, and no heart rhythm Patients with abnormalities, macular edema, tumors and immunosuppressants were used as experimental subjects, and 12 people were matched with clinical and imaging characteristics as controls.

[0028] 3. Experimental method

[0029] Patients were divided into fingolimod treatment group and control group, the control group received standard cerebral hemorrhage treatment; fingo...

Embodiment 2

[0042] Take 50g of fingolimod and 2450g of starch, mix 950g of starch with water to make a thin slurry, then gradually add the remaining starch and all of fingolimod to the slurry under stirring, stir all the ingredients evenly, make granules, and then Sieve and dry to form granules.

Embodiment 3

[0044] Take 50g of fingolimod, 2300g of starch, and 150g of magnesium stearate, mix 950g of starch and water to make a thin slurry, and then gradually add the remaining starch, all of fingolimod and all of the stearin to the slurry while stirring Magnesium acid, all stirred evenly, dried and compressed into tablets, film-coated to form tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a new use of fingolimod and its structural analog in the preparation of cerebral hemorrhage treatment medicines, and further clarifies a treatment mechanism, an effective dosage, a suitable dosage form, and a concrete compound referred to the structural analog. Experiments prove that fingolimod and its structural analog can alleviate lymphocyte infiltration caused by cerebral hemorrhage, and the above alleviation effect can be used as a new cerebral hemorrhage target in order to determine the new use of the fingolimod and its structural analog in the preparation of cerebral hemorrhage treatment medicines based on the above property of the fingolimod and its structural analog. The clinic adaptation disease of the fingolimod and its structural analog is enlarged, and the participation of immune cells in the pathological lesion of the cerebral hemorrhage is disclosed. The medicines prepared in the invention have a substantial curative effect on the cerebral hemorrhage, and have a protruding popularization prospect.

Description

technical field [0001] The present invention relates to a new application of fingolimod and its structural analogues, in particular to an application of fingolimod and its structural analogues in the preparation of medicaments for treating cerebral hemorrhage. Background technique [0002] Cerebral hemorrhage is a common clinical disease with high morbidity and mortality rates. The current conventional treatment methods are surgical therapy and drug supportive therapy. Among them, surgical therapy is an effective treatment method generally recognized in the technical field. However, due to the limitations of factors such as its high risk, high cost, and high physical requirements for patients, the scope of use has been affected. At present, the main mechanism of drug supportive therapy includes dehydration, lowering intracranial pressure, lowering blood sugar, lowering lipids, etc., all of which are indirect effects, and their curative effects are not exact. To sum up, ther...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/137A61P29/00A61P25/00
CPCA61K31/137A61K9/1652A61K9/2059A61P7/04A61P9/00A61P25/00A61P29/00
Inventor 施福东付莹闫亚平郝峻巍于春水张宁男楠任丽李瑀靖孙娜韩伟金薇娜
Owner 施福东
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com